CriticalSSRI (selective serotonin reuptake inhibitor)×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative
Updated · Methodology
Mechanism
Citalopram is a potent and selective inhibitor of serotonin reuptake (citalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Tranylcypromine irreversibly and non-selectively inhibits monoamine oxidase (MAO) types A and B and so prevents the inactivation of serotonin, noradrenaline and dopamine inside cells and neurons (tranylcypromine SmPC, AEMPS, section 5.1). Combining drugs that increase serotonin availability with MAO inhibitors can cause serotonin syndrome (tranylcypromine SmPC, AEMPS, section 4.4). Serious, sometimes fatal reactions have been reported with citalopram and MAO inhibitors (citalopram SmPC, AEMPS, section 4.5). Tranylcypromine and its metabolites are excreted within 24 hours, but full MAO activity returns only after 3–5 days (tranylcypromine SmPC, AEMPS, section 5.1). According to the US label, MAO inhibition may persist for up to 10 days (tranylcypromine label, US Food and Drug Administration, FDA, section 5.9). The documents describe no pharmacokinetic interaction for this pair: tranylcypromine strongly inhibits the enzyme CYP2A6, which plays little part in the metabolism of most drugs, and CYP2C19, CYP3A4 and CYP2D6 metabolise citalopram (tranylcypromine and citalopram SmPCs, AEMPS, section 4.5).
Symptoms
The interaction of citalopram with a monoamine oxidase (MAO) inhibitor presents with hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes including confusion, irritability and extreme agitation progressing to delirium and coma (citalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Serious, sometimes fatal reactions have also been reported in patients who had recently stopped a selective serotonin reuptake inhibitor and started an MAO inhibitor (citalopram SmPC, AEMPS, section 4.5). According to the US tranylcypromine label, serotonin syndrome may also include hallucinations, fast heart rate, dizziness, sweating, flushing, tremor, overactive reflexes, poor coordination, seizures, nausea, vomiting and diarrhoea (tranylcypromine label, US Food and Drug Administration, FDA, section 5.3). Fatal cases have been reported, including in patients treated with tranylcypromine. When tranylcypromine was combined with serotonin reuptake inhibitors, the picture sometimes resembled neuroleptic malignant syndrome (FDA tranylcypromine label, section 5.3).
Management
The combination is contraindicated. The Spanish tranylcypromine summary of product characteristics (SmPC) prohibits combining tranylcypromine with any selective serotonin reuptake inhibitor. The Spanish citalopram SmPC prohibits combining citalopram with monoamine oxidase (MAO) inhibitors, and according to its own SmPC tranylcypromine belongs to this group (tranylcypromine and citalopram SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 5.1). The US labels agree. The citalopram label contraindicates citalopram in patients taking MAO inhibitors or within 14 days of stopping them, and the tranylcypromine label lists this group of antidepressants among contraindicated drugs (citalopram and tranylcypromine labels, US Food and Drug Administration, FDA, sections 4 and 4.1). Start citalopram no earlier than 14 days after stopping tranylcypromine (citalopram SmPC, AEMPS, section 4.3, and FDA label, section 2.5; tranylcypromine SmPC, AEMPS, section 4.2). The documents give different intervals between stopping citalopram and starting tranylcypromine: at least 7 days in the Spanish citalopram SmPC, at least 14 days in the US citalopram label, and about 5 half-lives of citalopram and its active metabolites in the Spanish tranylcypromine SmPC. The half-life of citalopram is about 33 hours (citalopram SmPC, AEMPS, sections 4.3 and 5.2, and FDA label, section 2.5; tranylcypromine SmPC, AEMPS, section 4.2). If signs of serotonin syndrome appear, stop citalopram at once and start symptomatic treatment (citalopram SmPC, AEMPS, section 4.4), and stop tranylcypromine and any other serotonergic drugs at once as well (FDA tranylcypromine label, section 5.3). Treat severe serotonin syndrome caused by the interaction in the same way as tranylcypromine poisoning: in intensive care, with close monitoring of pulse, blood pressure, breathing and temperature. For severe agitation and marked muscle rigidity, the SmPC recommends benzodiazepines, and cyproheptadine may be tried to block serotonin receptors (tranylcypromine SmPC, AEMPS, section 4.9). Explain to the patient that after tranylcypromine is stopped, some drugs need a drug-free interval before they can be started (FDA tranylcypromine label, section 17).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Citalopram, Seropram 30 mg (nº registro 63564) (2024)– AEMPS, CIMA, nº registro 63564 (Seropram 30 mg comprimidos recubiertos con película, Lundbeck), revisión 01/2024, secciones 4.2, 4.3, 4.4, 4.5 y 5.1
- FDA: Celexa (citalopram) – Prescribing Information (2023)– FDA, DailyMed SPL, Allergan, setid 4259d9b1-de34-43a4-85a8-41dd214e9177, version 40, revised 10/2023, sections 4, 5.2, 5.3, 5.4, 7, 12.3 and 17
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.3 (2026)– AEMPS, CIMA, nº registro 88524, revisión 08/2026, sección 4.3
- FDA: Parnate (tranylcypromine) prescribing information (2025)– FDA, DailyMed, Advanz Pharma, setid b72d8187-dfcc-4ea0-b5e9-c0be95b69a27, revised 07/2025, sections 4.1, 5.3, 5.9 and 7.1